Raymond Winquist is Head & Translational Research at Xenon Pharmaceuticals Inc. (XENE). They have made 1 open-market trade across 1 company since 2017, most recently 2017-08-18.
CIK 0001670668
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3K since 2017, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XENE | 1,000 | $33K |
Shares reported on the most recent Form 4, priced at the 2017-08-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | BUY | 2017-08-18 | 2017-08-21 | $3.00 | $3K | +3.3% | -4.9% | -22.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.